Growing Focus on Stem Cell Research Is Expected to Boost the Global Cell Culture Protein Surface Coating Market Through 2019
The Global Cell Culture Protein Surface Coating Market is expected to post a CAGR of 12.91% from 2014 to 2019, thanks to a growing focus on stem cell research, according to a new report from research firm TechNavio.
Stem cell therapy plays a vital role in the treatment of several serious diseases including neurodegenerative diseases, cardiac diseases and diabetes. Presently, it is most commonly used for bone marrow transplants.
Cell culture protein surface coating products help researchers improve the adhesion, proliferation and growth of cells being cultured for these treatments.
“The high potential of stem cells in the treatment of severe diseases has resulted in demand for advanced cell culture products for stem cell production and study,” says Faisal Ghaus, Vice President of TechNavio.
The latest report by TechNavio draws attention to animal-free synthetic protein surface coatings that have a broad range of applications in several areas, including biopharmaceutical production and other research. There has been a huge demand for these coatings from the pharmaceutical and biotechnology industries, as they reduces the risk of contamination.
“Many vendors like BD are focusing on the development of animal-free synthetic protein surface coating products so as to meet increasing industry demand,” says Ghaus.
Key Information Covered in the Report:
• Market segmentation, size and forecast through 2019
• Market Growth Drivers:
• Growing Focus on Stem Cell Research
• For a full detailed list, view the report.
• Market Challenges:
• Disadvantages of Animal-derived Protein Surface Coatings
• For a full detailed list, view the report.
• Market Trends:
• Animal-free Synthetic Protein Surface Coating
• For a full detailed list, view the report.
Key Questions Answered in this Report:
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
• Key Vendors:
• Becton, Dickinson and Co. (BD)
• Corning Inc.
• EMD Millipore Corp.
• Sigma-Aldrich Corp.
• Other Prominent Vendors:
• Abcam
• BioMedTech Laboratories
• Cedarlane Laboratories
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.